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Molassiotis is the author of about 40 reviews, all of which are
prone to the shortcomings he highlights. His statement, “I urge
researchers in the field not to proliferate publications of ‘sys-
tematic’ reviews of a very small number and of admittedly
poor/low quality level trials”, is thus surprising to say the least.
The main point of his response seems to be that “systematic
reviews of few and low-quality studies do not help anybody”.
We feel that such articles can still be useful, for instance, for
disclosing important deficits in our current knowledge.
In making this point, Molassiotis seems to display a lack of
understanding of science in general and systematic reviews in
particular. Here are a few of his most obvious errors:
He asks “didn’t we know this [the result of a systematic
review] before the review”? It seems obvious to us that the
findings of a review can never be known before the research
has been conducted.
He refers to “systematic reviews on the same topic by
several different authors”. Yet a closer look at the actual
articles he quotes informs us that they are, in fact, on subtly
different subjects.
He claims that we believe that “anything that does not have
a sham arm is not a good trial”. Yet we never stated anything
like this. We would, however, argue that, for determining
whether an intervention has therapeutic effects beyond place-
bo, a placebo/sham control is helpful.
He argues that controlling for placebo effects in acupunc-
ture trials is done “to give some ‘science’ credentials to such
trials and mimic drug trial placebo-controlled designs”. We
would counter that the sole reason for doing this is to be able
to differentiate between specific and non-specific therapeutic
effects; in our view, this is important for determining the value
of any treatment.
He states, “I am questioning the ethics” [of such sham-
controlled studies]. We would insist that differentiating between
placebo and specific effects is a crucial ethical task of clinical
research.
He claims that “bringing all acupuncture trials togeth-
er as one treatment is like mixing apples and oranges”.
We would like to remind him that, by definition, sys-
tematic reviews are about summary judgements of this nature
and that most of his own reviews have followed exactly the
same principles.
Finally, we agree with him that “we should not deny patients
the possibility of experiencing symptom relief and health im-
provements because of sterile and incapacitating arguments
about how to carry out ‘proper’ acupuncture trials”. But we
need to point out that, before we can be sure that patients do
benefit from our interventions, we need to determine whether
they generate more good than harm. In our opinion, this re-
quires rigorous research, and any attempt to bypass this process
is likely to be counterproductive and unethical.
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